Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: BoNg-N-BoNg who wrote (5498)	2/22/1998 6:12:00 AM
From: Jenna	Respond to of 120523

Great Reports and Great Charts: CTI, IDPH, ALXN .. The first two companies came in last week with higher than expected earnings and their technical charts are compelling. CTI, recently upgraded and it blew away estimates of 38 cents with a report of 49 cents. That was a 62% increase from last years... $58 million in new orders were booked in the fourth quarter." The chart is in a strong uptrend above all it's moving averages. IDPH was on my earnings list.. It's a strong buy with technical breakouts. ALXN had its very first profitable quarter in December. It was upgraded to BUY by Josephtal.. with a 12-month price target of $25. ....By launching two highly profitable products by 2002, we believe the company will achieve stellar earnings." I played that one before and will do so again. The chart is strong.Relative Strength is extremely high. MFI (Market Facilitation Index) volume indicator and McClellan oscillator indicates that there is money flowing into this company and it's in the midst of a strong uptrend. The 50 day MOVING AVERAGE as well as the 10 day moving average. The 20 day MOVING AVERAGE is not. _____________________________________ Alexion Pharmaceuticals, Inc. was founded in 1992 and is engaged in the development of selective immunotherapeutic drugs that generally are designed to inhibit the disease-causing segments of the immune system while preserving the disease-preventing aspects of the immune system. The Company is developing three technology platforms: C5 Complement Inhibitors and Apogen T-Cell Therapeutics which together target severe cardiovascular and autoimmune disorders; and xenografts for organ transplants. On January 6 it was given a patent from the US Patent Trandemark Office: NEW HAVEN, Conn. Jan. 6 /PRNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN ) today announced that the United States Patent and Trademark Office has issued U.S. patent No. 5,705,732 entitled "Universal Donor Cells" which relates to the Company's xenotransplantation program. This U.S. patent covers transgenic animals expressing a crucial human complement inhibitor known as CD59. The patent was issued to the Oklahoma Medical Research Foundation (OMRF) and Yale University and is exclusively licensed to Alexion.

To: BoNg-N-BoNg who wrote (5498)	2/22/1998 10:21:00 AM
From: LastShadow	Read Replies (3) \| Respond to of 120523

DATM DATM broke its 17.125 resistance level Friday on a lot of volume and ticks. It may have a slight correction (or bigger one if the market is down Monday/Tuesday), but as long as it stays above Thursday's high it should be safe for a hold. The next two resistance levels are 19.25 and 22 based on the October and December tankings. If DATM makes a relative high (breaks 18) then my guess is that it will run close to 20. 39 period stochastics are in great position, as is the money flow and strength. lastshadow